The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

The British HIV Association (BHIVA) has recommended that everyone living with HIV aged 40 and over should take a statin to reduce their risk of heart disease, even if they do not have raised ...

A man dubbed the 'Geneva patient' appears to be the latest person cured of HIV after a stem cell transplant for cancer treatment. Unlike the other five known cases, however, he received stem cells ...

Doxycycline post-exposure prophylaxis (doxyPEP), which was found to be highly effective at preventing sexually transmitted infections (STIs) among gay men and transgender women, did not protect young ...

A man in southern California, dubbed the 'City of Hope patient', appears to be the latest person cured of HIV after receiving a stem cell transplant from a donor with a rare mutation, bringing the ...

The majority of South African HIV patients could be switched to the World Health Organization’s recommended first-line regimen if the country adopts advice from leading doctors. This would allow most ...

Despite the incredible efficacy of oral pre-exposure prophylaxis (PrEP) and 78 countries currently offering PrEP in some form, its effectiveness at reducing HIV incidence in the real world has been ...

Once again, a life expectancy study has shown that HIV-positive people who start antiretroviral therapy (ART) promptly and have good access to medical care live as long as their HIV-negative peers.

An Israeli biotech company has issued a misleading press release which has encouraged some media outlets to falsely suggest that a new drug, Gammora, may be able to cure HIV.

As pre-exposure prophylaxis (PrEP) use continues to grow, epidemiological evidence is starting to show an association between increases in PrEP uptake and declines in new infections. A new analysis ...

Final follow up of the HPTN 052 study of treatment as prevention shows no evidence of HIV transmission from people with fully suppressed viral load to their partners, four years after the first ...